Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Lorena Sanchez‐Felipe, Thomas Vercruysse, Sapna Sharma, et al.
Nature (2020) Vol. 590, Iss. 7845, pp. 320-325
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

Animal models for COVID-19
César Muñoz‐Fontela, William E. Dowling, Simon G. P. Funnell, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 509-515
Open Access | Times Cited: 800
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Science Immunology (2021) Vol. 6, Iss. 62
Open Access | Times Cited: 494
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 493
Circular RNA vaccines against SARS-CoV-2 and emerging variants
Liang Qu, Zongyi Yi, Yong Shen, et al.
Cell (2022) Vol. 185, Iss. 10, pp. 1728-1744.e16
Open Access | Times Cited: 374
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 293
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
Paul Bastard, Elizaveta Orlova, Leila Sozaeva, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 7
Open Access | Times Cited: 252
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
Ian A. McDonald, Sam M. Murray, Catherine J. Reynolds, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 232
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 193
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine
Paul Bastard, Eleftherios Michailidis, Hans-Heinrich Hoffmann, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 4
Open Access | Times Cited: 181
COVID-19 vaccination: The road ahead
Daniel M. Altmann, Rosemary J. Boyton
Science (2022) Vol. 375, Iss. 6585, pp. 1127-1132
Closed Access | Times Cited: 180
A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
Traci L. Bricker, Tamarand L. Darling, Ahmed O. Hassan, et al.
Cell Reports (2021) Vol. 36, Iss. 3, pp. 109400-109400
Open Access | Times Cited: 150
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
Jun Siong Low, Josipa Jerak, M. Alejandra Tortorici, et al.
Science (2022) Vol. 377, Iss. 6607, pp. 735-742
Open Access | Times Cited: 139
The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics
Wenbing Wu, Ying Cheng, Hong Zhou, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 139
Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, et al.
EBioMedicine (2021) Vol. 68, pp. 103403-103403
Open Access | Times Cited: 123
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
Manon Laporte, Valerie Raeymaekers, Ria Van Berwaer, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 4, pp. e1009500-e1009500
Open Access | Times Cited: 117
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
Majed Ghattas, Garima Dwivedi, Marc Lavertu, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1490-1490
Open Access | Times Cited: 113
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
Jim Baggen, Maarten Jacquemyn, Leentje Persoons, et al.
Cell (2023) Vol. 186, Iss. 16, pp. 3427-3442.e22
Open Access | Times Cited: 97
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Katie L. Flanagan, Emma Best, Nigel Crawford, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 94
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
David A. Meekins, Natasha N. Gaudreault, Jüergen A. Richt
Viruses (2021) Vol. 13, Iss. 10, pp. 1993-1993
Open Access | Times Cited: 93
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 77
A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters
Yangtao Wu, Xiaofen Huang, Lunzhi Yuan, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 606
Open Access | Times Cited: 74
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Nerea Zabaleta, Wenlong Dai, Urja Bhatt, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 9, pp. 1437-1453.e8
Open Access | Times Cited: 69
A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
Xueqiao Liu, Cindy Luongo, Yumiko Matsuoka, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 50
Open Access | Times Cited: 62
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang, Ying Lu, Yan‐Bo Zhao, et al.
Cell Research (2022) Vol. 32, Iss. 12, pp. 1068-1085
Open Access | Times Cited: 51
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top